- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
rexulti
Synonyms :
Class :
Dopamine Receptor Partial Agonists
Dosage Forms & Strengths
Tablet
0.25mg
0.5mg
1mg
2mg
3mg
4mg
Day 1-4: 1mg orally every day
Day 5-7: Adjust dosage to 2 mg every day
Day 8: Adjust to 4mg/day
Do not exceed 4mg/day
0.5
mg
Tablet
Orally
every day
Do not exceed 3mg/day
Dosage Forms & Strengths
Tablet
0.25mg
0.5mg
1mg
2mg
3mg
4mg
<13 years: Safety and efficacy not established
Day 1-4: 0.5 mg orally every day
Day 5-7: Adjust dosage to 1 mg every day
Day 8: Adjust to 2 mg/day
Do not exceed 4 mg/day
Not approved
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with brexpiprazole
brexpiprazole : they may diminish the serum concentration of CYP3A4 Inducers
brexpiprazole : they may diminish the serum concentration of CYP3A4 Inducers
may enhance the serum concentration of CYP3A4 inhibitors
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
it may increase the effects of each other
may increase the risk of sedation
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
It may enhance sedation when combined with oxycodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brexpiprazole
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism